The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are investigating a multi-state outbreak of Burkholderia cepacia infections.
The B. cepacia infections have occurred primarily in ventilated patients without cystic fibrosis and who are receiving treatment in intensive care units. In their preliminary update on June 24, 2016, the CDC and FDA reported that a contaminated liquid docusate product may be associated with cases in one state. According to an update released today, preliminary information still indicates that contaminated oral liquid docusate products may be related to B. cepacia complex infections in one state.
Currently, no lab or epidemiological data exists to suggest that oral capsule or enemas are affected. Until more data is available, the CDC continues to recommend that facilities not use any oral liquid docusate products for critically ill, ventilated, or immunosuppressed patients.
Healthcare facilities that see B. cepacia complex infections arise in non-cystic fibrosis patients or see clusters of these complex infections among cystic fibrosis patients should sequester all oral liquid docusate products.
The CDC also urged healthcare providers and laboratories to be vigilant about B. cepacia complex infections occurring among non-cystic fibrosis patients and should alert infection prevention staff when they occur. Also, clusters of B. cepacia infections occurring among cystic fibrosis patients should be reported when rates appear higher than endemic rates.
An update by the CDC will be released by July 7, 2016.
For more information visit CDC.gov.